Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

Currencywolf Jul. 21 at 9:03 PM

Been banking off @TopSarge alerts these past few weeks. The entries have been insane! Don’t sleep, go give him a follow 🔥 $XE $UMAC $ABEO $NOK fueling up to moon

0 · Reply

alexpitti Jul. 21 at 9:01 PM

$ABEO this person is an idiot. the stock does its own thing everyday

0 · Reply

topstockalerts Jul. 21 at 8:38 PM

$ABEO this stock seems to be doing its own thing today.

0 · Reply

tmoney4572 Jul. 21 at 8:20 PM

$ABEO

1 · Reply

tmoney4572 Jul. 21 at 8:19 PM

$ABEO boom bitch

0 · Reply

Abelixe Jul. 21 at 8:03 PM

$ABEO Funny how sentiment can change in a matter of hours. After the recent pullback it would’ve been easy for sellers to stay in control, but buyers kept stepping in and we finished green. That’s the kind of price action I like to pay attention to. For me, the thesis hasn’t changed. The launch is progressing, more treatment centers continue to come online, and now it’s all about execution. Sometimes the market gets impatient long before the story has had a chance to unfold. Added some more around $6.26. Happy to sit back and see where the next few quarters take us.

0 · Reply

Abelixe Jul. 21 at 8:02 PM

0 · Reply

TragicRain Jul. 21 at 8:00 PM

$ABEO - literally every time you open you mouth....LOL..... We love you Mrs. Goo!!!!

1 · Reply

JimiJoJeeter Jul. 21 at 7:48 PM

$ABEO 😉

1 · Reply

dark_gamma Jul. 21 at 7:38 PM

$ABEO Options Flow Heatmap Last: $6.38 Notable Resistance Levels: $6.52 ($1.0M) | $6.62 ($1.1M) Critical Support Zones: $6.20 ($1.2M) | $6.04 ($0.9M) | $6.00 ($2.8M) Want to stay ahead of the market? Follow us for daily updates on key tickers #ABEO #Options #Trading #GEX #GammaExposure

0 · Reply

Abeona Therapeutics activates Cincinnati Children’s as treatment center

Jul 21, 2026, 7:30 AM EDT - 12 hours ago

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Jul 1, 2026, 7:30 AM EDT - 20 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2026, 9:00 AM EDT - 5 weeks ago

Abeona Therapeutics Transcript: AGM 2026

Jun 10, 2026, 7:00 AM EDT - 5 weeks ago

Abeona Therapeutics Slides: Investor presentation

Jun 4, 2026, 3:10 PM EDT - 6 weeks ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

May 13, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics Slides: Q1 2026

2026-05-13T12:17:05.000Z - 2 months ago

Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)

May 13, 2026, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

May 11, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

May 4, 2026, 8:30 AM EDT - 2 months ago

Abeona Therapeutics® Announces Date of First Quarter Financial Results

May 4, 2026, 8:00 AM EDT - 2 months ago

Abeona Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Abeona Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Abeona Therapeutics Proxy statement: Proxy filing

Apr 14, 2026, 7:00 AM EDT - 3 months ago

Abeona Therapeutics Slides: Corporate presentation

Apr 7, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Apr 2, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

2026-03-17T21:40:20.000Z - 4 months ago

Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global

Mar 17, 2026, 8:30 AM EDT - 4 months ago

Abeona Therapeutics Earnings Call Transcript: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 4 months ago

Abeona Therapeutics Annual report: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 4 months ago

Abeona Therapeutics Earnings release: Q4 2025

2026-03-17T11:35:14.000Z - 4 months ago

Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year

Mar 17, 2026, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Mar 10, 2026, 8:40 AM EDT - 4 months ago

Abeona Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:41:57.000Z - 4 months ago

Abeona Therapeutics provides business update on momentum in Zevaskyn launch

Mar 9, 2026, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mar 3, 2026, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

2025-12-31T12:35:26.000Z - 7 months ago

Abeona Therapeutics announces employee inducement grants

2025-12-15T12:36:04.000Z - 7 months ago

Abeona Therapeutics appoints Mohamad Tabrizi as CBO

Dec 15, 2025, 7:30 AM EST - 7 months ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

2025-12-11T12:35:25.000Z - 7 months ago

Abeona Therapeutics announces new treatment center for Zevaskyn in Texas

Dec 11, 2025, 7:30 AM EST - 7 months ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

2025-12-08T12:35:33.000Z - 8 months ago

Abeona Therapeutics announces first patient treatment with ZEVASKYN

Dec 8, 2025, 7:30 AM EST - 8 months ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

2025-12-01T12:35:41.000Z - 8 months ago

Abeona Therapeutics reports employee inducement grants

Nov 13, 2025, 1:20 PM EST - 8 months ago

Abeona Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-12T19:20:27.000Z - 8 months ago

Abeona Therapeutics price target lowered to $19 from $20 at Stifel

Nov 12, 2025, 8:30 AM EST - 8 months ago

Abeona Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Abeona Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

Abeona Therapeutics Earnings release: Q3 2025

2025-11-12T12:36:04.000Z - 8 months ago

Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)

2025-11-12T12:35:51.000Z - 8 months ago

Abeona Therapeutics sees cash runway for over two years

Nov 12, 2025, 7:30 AM EST - 8 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 9 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

2025-11-03T12:35:07.000Z - 9 months ago

Abeona Therapeutics announces employee inducement grants

2025-10-30T14:50:28.000Z - 9 months ago

Abeona Therapeutics announces permanent J-Code for ZEVASKYN

Oct 30, 2025, 10:45 AM EDT - 9 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

2025-10-20T12:47:35.000Z - 9 months ago

Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development

Oct 20, 2025, 8:30 AM EDT - 9 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 13, 2025, 7:30 AM EDT - 10 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 8, 2025, 7:30 AM EDT - 10 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Sep 9, 2025, 2:00 PM EDT - 11 months ago

Abeona Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:20 AM EDT - 11 months ago

Abeona Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Quarterly report: Q2 2025

Jul 29, 2025, 10:00 AM EDT - 1 year ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 1 year ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 1 year ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 4, 2025, 11:40 AM EDT - 1 year ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:46 AM EDT - 1 year ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:07 AM EDT - 1 year ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 29, 2025, 6:06 AM EDT - 1 year ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 1 year ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Abeona Therapeutics Proxy statement: Proxy Filing

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Annual report: Q4 2024

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Abeona Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Abeona Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 12, 2024, 7:00 AM EST - 1 year ago

Abeona Therapeutics Proxy statement: Proxy Filing

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Sep 19, 2024, 9:45 AM EDT - 1 year ago

Abeona Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 1:30 PM EDT - 2 years ago

Abeona Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 14, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 11, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 9, 2024, 9:45 AM EDT - 2 years ago

Abeona Therapeutics Transcript: Stifel Virtual Cell Therapy Forum

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Abeona Therapeutics Registration statement: Registration Filing

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Abeona Therapeutics Registration statement: Registration Filing

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Currencywolf Jul. 21 at 9:03 PM

Been banking off @TopSarge alerts these past few weeks. The entries have been insane! Don’t sleep, go give him a follow 🔥 $XE $UMAC $ABEO $NOK fueling up to moon

0 · Reply

alexpitti Jul. 21 at 9:01 PM

$ABEO this person is an idiot. the stock does its own thing everyday

0 · Reply

topstockalerts Jul. 21 at 8:38 PM

$ABEO this stock seems to be doing its own thing today.

0 · Reply

tmoney4572 Jul. 21 at 8:20 PM

$ABEO

1 · Reply

tmoney4572 Jul. 21 at 8:19 PM

$ABEO boom bitch

0 · Reply

Abelixe Jul. 21 at 8:03 PM

0 · Reply

Abelixe Jul. 21 at 8:02 PM

0 · Reply

TragicRain Jul. 21 at 8:00 PM

$ABEO - literally every time you open you mouth....LOL..... We love you Mrs. Goo!!!!

1 · Reply

JimiJoJeeter Jul. 21 at 7:48 PM

$ABEO 😉

1 · Reply

dark_gamma Jul. 21 at 7:38 PM

0 · Reply

Abelixe Jul. 21 at 7:37 PM

$ABEO

0 · Reply

AMP19 Jul. 21 at 7:34 PM

$ABEO nice recovery

0 · Reply

creditgoo Jul. 21 at 7:12 PM

$ABEO i was told good news makes stock go.up

0 · Reply

jbernard Jul. 21 at 6:34 PM

$ABEO Anyone who sells their shares at this time, is making a serious big mistake. This equity should definitely rise with the new facilities, their execution, new products in FDA review, all in a positive line. Years ago, my daughter got her Down Payment on her home, from a similar bio, with similar traits. Do Not Sell.

1 · Reply

Pharma3000 Jul. 21 at 6:12 PM

$ABEO Therapeutics has already reached its goal of activating seven Qualified Treatment Centers (QTCs) for ZEVASKYN® by the end of 2026, following the activation of Cincinnati Children's.👏👏👏

0 · Reply

JimiJoJeeter Jul. 21 at 6:08 PM

$ABEO I'm m thinking this closes slightly positive today.

0 · Reply

Filvul Jul. 21 at 2:55 PM

$ABEO nice to get some at this level, 7 centers, patient build-up; demand is unfortunately there; this will see the target price by the end of H1 2027. Prove me wrong...

0 · Reply

Tradingistheway Jul. 21 at 2:51 PM

$ABEO $RCON

0 · Reply

tmoney4572 Jul. 21 at 2:47 PM

$ABEO these shares are a fucking steal right now

0 · Reply

Abelixe Jul. 21 at 2:35 PM

$ABEO Added some more here. Feels like a great entry point in my opinion. The price has come down, but the story hasn’t. Happy to build while others are taking profits.

0 · Reply

acm20 Jul. 21 at 2:29 PM

$ABEO Profit taking, manipulation, shorting or any/all of the above I presume. Seventh QTC news is positive imo.

0 · Reply

TragicRain Jul. 21 at 2:28 PM

$ABEO - LoL - when the bros that have been pumping this - tried to sell on news...and that didnt pan out for them....if it drops into the $5's I buy more....goal is and will be eventually be 10k shares. New Center was just announced.... big long picture...this is great news....

0 · Reply

Market Cap	398.97M
Revenue (ttm)	5.82M
Net Income (ttm)	71.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,223.02%
Debt to Equity Ratio	0.12

Volume	1,569,100
Avg Vol	1,277,112
Day's Range	N/A - N/A
Shares Out	57.00M
Stochastic %K	11%
Beta	1.34
Analysts	Strong Sell
Price Target	$19.71